Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 329 results for antibiotics

  1. FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)

    NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .

    Medtech innovation briefing
    Published
    26 August 2020

  2. Switching from inpatient intravenous to outpatient oral antibiotic therapy in patients with neutropenic sepsis:- A randomised controlled trial should be undertaken to evaluate the clinical and cost effectiveness of stopping intravenous antibiotic therapy and switching to oral therapy within the first 24 hours of treatment in patients with neutropenic sepsis who are having treatment with intravenous antibiotics. The outcomes to be measured are overtreatment, death, need for critical care, length of hospital stay, duration of fever and quality of life.

    Question Switching from inpatient intravenous to outpatient oral antibiotic therapy in patients with neutropenic sepsis:- A randomised...

    Research recommendation
    Published
    9 June 2015

  3. Is the application of antiseptics and antibiotics in the operative field before wound closure, clinically and cost effective in reducing surgical site infection rates?

    NG125/4 Question Is the application of antiseptics and antibiotics in the operative field before wound closure, clinically and cost...

    Research recommendation
    Published
    16 August 2019

  4. Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)

    NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus

    Medtech innovation briefing
    Published
    21 April 2015

  5. Intrapartum care (NG235)

    This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.

    NICE guideline
    Last updated
    14 November 2025
    View recommendations

    Sections for NG235

  6. Intrapartum antibiotics: What is the clinical and cost effectiveness of intrapartum antibiotics for women with meconium-stained amniotic fluid?

    NG195/10 Question Intrapartum antibiotics: What is the clinical and cost effectiveness of intrapartum antibiotics for women...

    Research recommendation
    Published
    6 August 2021

  7. Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)

    Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.

    Technology appraisal guidance
    Published
    27 March 2013
    View recommendations

    Sections for TA276

  8. AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46)

    NICE has developed a medtech innovation briefing (MIB) on the AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis

    Medtech innovation briefing
    Published
    15 December 2015

  9. Antibiotics for suspected early-onset infection: What is the incidence and severity of adverse effects with antibiotics used to prevent or treat early-onset neonatal infection?

    Question Antibiotics for suspected early-onset infection: What is the incidence and severity of adverse effects with...

    Research recommendation
    Published
    6 August 2021

  10. Prophylactic antibiotics for respiratory disorders:- Are prophylactic antibiotics clinically and cost effective in the management of respiratory symptoms in adults with cerebral palsy with significant respiratory comorbidity?

    NG119/4 Question Prophylactic antibiotics for respiratory disorders:- Are prophylactic antibiotics clinically and cost...

    Research recommendation
    Published
    8 March 2019

  11. MolecuLight i:X for wound imaging (MIB212)

    NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .

    Medtech innovation briefing
    Published
    18 June 2020

  12. Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of different antibiotics, doses and regimens of prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations?

    Question Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of different...

    Research recommendation
    Published
    13 February 2019

  13. Antibiotics for suspected early-onset infection: What is the incidence in England and Wales of resistance to commonly used antibiotics among bacteria that cause early-onset neonatal infection?

    Question Antibiotics for suspected early-onset infection: What is the incidence in England and Wales of resistance to commonly used...

    Research recommendation
    Published
    6 August 2021

  14. Antibiotics for suspected early-onset neonatal infection: What is the optimal duration of treatment (course length) in babies who receive antibiotics for confirmed early-onset neonatal infection?

    Recommendation ID NG195/4 Question Antibiotics for suspected early-onset neonatal infection: What is the optimal duration of treatment

    Research recommendation
    Published
    6 August 2021

  15. Antibiotics for suspected early-onset infection: What are the core exposures and outcomes that should be used to evaluate clinical effectiveness of antibiotics to prevent or treat early- onset neonatal infection?

    Recommendation ID NG195/14 Question Antibiotics for suspected early-onset infection: What are the core exposures and outcomes that should

    Research recommendation
    Published
    6 August 2021